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ABSTRACT
As the impact of COVID-19 on society became apparent, the engineering and scientific community recognized the need for innovative solu-
tions. Two potential roadmaps emerged: developing short-term solutions to address the immediate needs of the healthcare communities and
developing mid/long-term solutions to eliminate the over-arching threat. However, in a truly global effort, researchers from all backgrounds
came together in tackling this challenge. Short-term efforts have focused on re-purposing existing technologies and leveraging additive man-
ufacturing techniques to address shortages in personal protective equipment and disinfection. More basic research efforts with mid-term and
long-term impact have emphasized developing novel diagnostics and accelerating vaccines. As a foundational technology, photonics has con-
tributed directly and indirectly to all efforts. This perspective will provide an overview of the critical role that the photonics field has played
in efforts to combat the immediate COVID-19 pandemic as well as how the photonics community could anticipate contributing to future
pandemics of this nature.
© 2020 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license
(http://creativecommons.org/licenses/by/4.0/). https://doi.org/10.1063/5.0021270., s
I. INTRODUCTION
From microscopy1–3 to optical communications,4–6 optical
technologies permeate nearly every aspect of society. Therefore,
when confronted with the challenges of a global pandemic,7–12 it
is not surprising that many solutions have been found in photonic
devices and developed by optical engineers. Although research and
development efforts have been hindered by work from home con-
ditions and manufacturing has been delayed by shortages in the
supply chain,13 photonics researchers and companies have made sig-
nificant contributions to diagnostics and personal protective equip-
ment (PPE) by both adapting existing systems and inventing new
technologies (Fig. 1).8,10,14
The short-term solutions have focused on inventing easily
manufacturable biomedical devices and on addressing the global
shortages in personal protective equipment (PPE) to reduce spread,
particularly in healthcare settings. This work has included the
development of fabric face masks, 3D printable face shields, and
respirators for healthcare workers. While optical technologies played
only a supporting role in the PPE fabrication efforts, they directly
contributed to PPE re-use. Specifically, numerous approaches that
leverage the ability of ultraviolet-C (UV-C) or UV germicidal irradi-
ation (UVGI) to serve as a disinfection method were developed.15–17
In the face of the pandemic, many countries accelerated approvals
of various technologies or granted emergency use authorization. As
a result, these safety measures were available to the healthcare com-
munity within weeks. In addition, many existing technologies were
either re-configured or adapted to more directly address COVID-19
needs.
The mid-term and long-term solutions emphasized developing
methods for tracking and accelerating pharmacological solutions.
Accurate tracking of infected individuals to reduce and to contain
COVID-19 spread requires a combination of software and hard-
ware (diagnostics). While software solutions were quickly launched,
accurate diagnostics have been more challenging to deploy, in
part, because of the numerous fundamental questions about the
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FIG. 1. Overview of the different tech-
nological solutions being pursued to
address COVID-19.
pathophysiology of COVID-19 that remain unanswered. As a result,
many diagnostics, including optical diagnostics, are finding an
immediate use in understanding the nature of the disease.18,19
In parallel, researchers are also pursuing the development of
therapeutics and vaccines. While outside of the scope of this perspec-
tive, numerous potential strategies are being investigated with the
hope that one will be proven effective quickly.20–33 Additionally, it
is notable that the fundamental approach to vaccine and therapeutic
trials has also been re-envisioned, greatly accelerating the potential
timeline of availability.
This perspective will focus on the role of optics in health-
care, discussing technologies for disinfection and diagnostics. For
both topics, a brief background is followed by a more in-depth
discussion on recent innovations and their impact to society. We
end by discussing the future prospects and open questions in the
field.
II. EXISTING HEALTHCARE MONITORING
TECHNOLOGIES
Since the time of Hippocrates, diagnosis of disease has played
a key role in medicine and healthcare. Initial approaches relied on
palpation and analyzing physical symptoms, such as temperature.
As technology progressed, physicians and scientists developed more
advanced diagnostic methods, for example, analyzing the cell shape
and color of red blood cells. In the modern era, medical diagnostics
has transitioned from the cellular to the molecular level, and it typ-
ically relies on an integrated transducer platform to facilitate device
fabrication. Additionally, with the development of instruments such
as MRI, NMR, and CT, imaging is no longer limited to ex vivo and
in vitro methods.
Integrated diagnostic platforms for detecting either molecu-
lar or protein indicators of disease based on electrical, mechani-
cal, and optical transduction mechanisms have been demonstrated.
All three types of sensors have been used extensively in research
applications. For example, mechanical sensor arrays based on can-
tilevers have been used to weigh individual cancer cells, investigat-
ing the efficacy of different therapeutics. Electrical sensors based
on nanopore arrays have been used to analyze and sequence DNA,
and optical sensors based on plasmonics have been used to under-
stand antibody–antigen binding reactions. However, the majority of
commercialized diagnostic systems that are utilized in medical set-
tings for disease diagnosis are based on optical technologies due to
the simplicity of the optical signal readout and compatibility with a
wide range of sample types. For example, optical biosensing meth-
ods have increased the precision and accuracy of disease diagnosis,
optical detectors have enabled disease progression monitoring, and
laser-based treatments and therapeutics have improved the ther-
apeutic efficacy and shortened recovery times.34–38 In the context
of COVID-19, many existing technologies have been rapidly re-
configured and applied for both diagnostics in a healthcare setting
and at-home monitoring of disease progression.
Most molecular diagnostic platforms for healthcare settings
rely on detecting either the RNA or the DNA of the pathogen39–43
or the immune system response to the pathogen (antibody).38,44–47
Therefore, before a diagnostic can be developed, it is necessary to
either obtain and sequence the RNA or DNA or identify the anti-
body generating the response. From a diagnostic perspective, it
is more straightforward to perform the former because it directly
detects the virus. Additionally, RNA or DNA methods detect the
active circulating pathogen, potentially in pre-symptomatic patients
(Fig. 2).18,27,39,48 In the case of COVID-19 and other highly conta-
gious pathogens, this ability is critical as it allows preventative mea-
sures to reduce transmission to be taken, potentially preventing or
containing outbreaks.12,18
In contrast, an antibody-based diagnostic infers the presence of
the virus through the person’s immune system response.49 There-
fore, it is an indirect indicator of infection, and it is much more
susceptible to incorrect findings. Additionally, it requires knowl-
edge of the antibody that is specific to the pathogen. Importantly,
because antibody-based techniques will only show positive diag-
nosis after the immune system has responded, these methods are
FIG. 2. The concentration of RNA and antibodies indicative of a SARS-CoV-2 infec-
tion varies with time since infection. Adapted with permission from Lee et al., Front.
Immunol. 11, 879 (2020). Copyright 2020 Author(s), licensed under a Creative
Commons Attribution 4.0 License.
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unable to detect pre-symptomatic infections (Fig. 2). Therefore, in
the case of COVID-19, it is not surprising that the development and
widespread adoption of an RNA-based test occurred well in advance
of an antibody-based assay.14,19,50–53
Once the RNA sequence was established, conventional DNA
methods, namely, reverse transcription-polymerase chain reaction
(RT-PCR), in combination with existing sample handling and pro-
cessing protocols, were leveraged to convert the viral RNA located
in the nasal swab sample to DNA and to amplify the DNA
concentration to detectable levels using RT-PCR (Fig. 3).32,48,54,55
While RT-PCR increases the sample concentration, detection is
typically performed using quantitative-PCR (qPCR), which is a
fluorescence-based sensing method.42,43 It is important to note
that RT-PCR and qPCR are distinctly different steps in this pro-
cess; however, qPCR and RT-PCR can be performed simultane-
ously, allowing the concentration to be measured in real time.
This approach is often called real-time RT-PCR (or RT-qPCR) in
shorthand.
As a fluorescent-based detection technology that relies primar-
ily on the visible spectrum, qPCR (and RT-qPCR) has benefited
greatly from numerous advances in optical technology, ranging from
optical sources to detectors as well as novel fluorophores. The reduc-
tion in footprint and increased lifetime of LEDs relative to conven-
tional bulbs has allowed for a reduction in system size and lowered
maintenance and operating costs. For high performing systems, the
availability of narrow linewidth sources and high sensitivity detec-
tors covering a wide spectral range has enabled signal multiplex-
ing. When combined with robotic samplers for automated han-
dling, a single instrument can analyze hundreds of samples per hour
with low false positive/false negative rates. Although the technology
required for PCR technologies has improved significantly, because
PCR detects RNA and DNA directly from the virus, PCR technolo-
gies can only detect active infections, and not past infections once
the patient recovers.
An alternative method that can detect both active and recov-
ered patients is based on antibody detection. These technologies
detect the immune system’s response to the infection.56 There-
fore, the first step in developing the assay is antibody discov-
ery21,29,44,57,58 and then establishing a reliable and high affinity
antibody production line. In addition, while the terms “antibody”
and “immunoglobulin” (Ig) are commonly used interchangeably,
the immune system produces several types of antibodies depend-
ing on the type of immune response and pathway.56 If sufficient
information is known about the temporal nature of the immune
response, a diagnostic that indicates both the presence and the pro-
gression of a disease can be developed, improving the diagnostic.
An example of this approach is detecting both the IgM and IgG
antibodies that are produced at different timepoints during infec-
tion (Fig. 2).56 However, these antibodies have very different struc-
tures and affinities, which contribute to their precision and accuracy
when used in a sensor. Therefore, it is important to understand
their biochemistry before architecting a sensor that relies on this
pair.
IgM is the largest antibody (Fig. 4), comprised of five
monomers arranged in a ring, resulting in ten binding sites. It is
poly-reactive and has low-avidity, allowing it to respond quickly to
unknown insults. The low avidity is fundamental to IgM’s opera-
tional principle and allows it to be the fastest responding antibody
FIG. 3. Comparison of PCR methods for diagnosis of COVID-19. (a) Two-step PCR. First, RNA is converted to DNA through RT-PCR. Then, DNA is quantified using qPCR.
This approach allows for optimization of both reactions, but it is more time-consuming than a one-step process. (b) One-step PCR. RT-PCR and qPCR are performed in the
same vial in parallel. This approach is faster, but the two reactions are not optimized. (c) Cartoon of the type of data that are generated and analyzed. Images created with
Biorender.com.
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FIG. 4. Immunoglobulin structure. (a) IgM structure is comprised of five monomers
with ten binding sites. (b) IgG structure is comprised of one monomer with two
binding sites. The binding sites are located at the end of the FAB region of the
monomer, in the variable region. Images created with Biorender.com.
of the immune system. However, in the context of diagnostics, this
property can result in high false positives. At the same time, the
rapid production of these IgM’s allows them to be an indicator of
active or recent infection, given their short lifetime. It takes the
immune system ∼1 week to produce IgM’s, and they only remain
in the circulatory system for approximately another week.
In contrast, IgG is comprised of a single monomer with two
adaptive binding sites (Fig. 4). Because it is generated in response
to a specific insult, it has moderate to high avidity for that insult.
While it takes a few weeks for IgG antibody concentrations to rise
and stabilize, IgG’s can circulate at a constant concentration for sev-
eral months to a lifetime. Therefore, they provide a good indicator of
past exposure. However, it is important to note that the concentra-
tion and avidity of IgG’s generated can be related to the magnitude
of the initial insult and the host immune system response. There-
fore, in the case of COVID-19, the concentration detected is not
a reliable indicator of time since exposure because neither of these
variables are known. On a side note, IgG’s are also responsible for
the long-term immunity provided by engineered vaccines, which
induce a strong immune system response. However, it is not clear
at this time if the presence of COVID-19 IgG’s indicates long-term
immunity.59
The majority of commercialized optical sensors for COVID-
19 antibody detection have focused on leveraging existing instru-
mentation for signal readout, such as microplate readers or
fluorescent imaging systems, or on developing point-of-care sys-
tems, including simple colorimetric indicators. These strategies vary
in their approach for IgG and IgM identification, the complex-
ity of the sample handling and chemistry protocols, the time-to-
result, and the information that can be provided (Table I). All
of these factors contribute to the false positive and false nega-
tive rates, which determine the accuracy and precision (or reli-
ability) of the finding. Therefore, it is important to recognize
that the term “antibody test” is a very broad classification given
a large variety of diagnostic tests that rely on the detection of
antibodies.
Among the different antibody diagnostic methods, the rapid
diagnostic test (RDT) is the most commonly recognized by the gen-
eral public.19,39,51,53 An example configuration of an RDT is shown
in Fig. 5. By simply monitoring the color of the two detection strips
(as well as the control strip), the user can make a diagnosis in
10 min–30 min with a small sample of blood. Not surprisingly, due
to their quick response time, low cost, and ease of use, these tests
have quickly gained popularity. However, due to limitations with
specificity of the reactants, the false positive and false negative rates
are significantly higher than those in RT-qPCR.14 Therefore, while
RDTs can be used as one piece of information, decisions regard-
ing healthcare should not rely solely on antibody test results until
higher affinity antibodies have been developed and can be reliably
manufactured.62
In diagnosing and monitoring COVID-19 progression, a base
set of physical symptoms that are simple to analyze has been iden-
tified, including temperature and blood oxygen saturation levels
among others.62 While both measurements can indicate multiple
other illnesses, they can still provide information quickly and inex-
pensively, without requiring blood samples, nasal swabs, or expen-
sive equipment. Additionally, once diagnosed, the measurements
can allow disease progression to be tracked from home, reducing the
burden on the healthcare system.
Stand-off cameras based on infrared (8 μm–14 μm) detec-
tors have been used extensively in the scientific community
for some time to perform thermal imaging, particularly in the
atmospheric and aerospace communities but also in environmental
TABLE I. Overview of common diagnostic tests for COVID-19.
Time for Antibody Concentration Effectiveness
Test Mechanism the test presence of antibodies of antibodies
Rapid diagnostic Substrate changes color to indicate 10 min–30 min Yes No No
test44 the presence of antibody
Neutralization Patient sample and virus are mixed
3 days–5 days Yes No Yesassay with cells to determine the presence and
test60 efficacy of protecting cells
ELISA,53,61 Substrate changes or emits color a series
2 h–5 h Yes Yes Nochemiluminescent to indicate the presence of antibody;
immunoassay of dilutions are run to obtain concentration
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FIG. 5. Schematic of the RDT. (a) The
RDT has two diagnostic lanes and a con-
trol lane. The conjugation pad contains
a COVID-19 antigen and a control anti-
body, both labeled with a metal nanopar-
ticle. The sample is wicked across the
conjugation pad and then across all three
lanes. (b) If a strip changes color, it
indicates that the antibody is present.
Images created with Biorender.com.
sciences for tracking global climate change. However, these detectors
were extremely large and expensive. Several years ago, in response
to SARS, stand-off imaging systems leveraging these thermal cam-
eras were developed for airports and other high-traffic areas to easily
and quickly monitor the temperatures of large populations of people.
However, the shift to handheld units required a significant reduction
in size and in cost as well as the integration of self-referencing capa-
bility. This combination was only recently accomplished. Currently,
stand-off measurements for monitoring temperature are a funda-
mental component of many corporate and government COVID-19
monitoring strategies. However, body temperature is not a perfect
indicator as asymptomatic carriers can transmit the virus yet have
no discernable temperature increase.
Blood oxygen saturation monitoring, also known as pulse
oximetry (or pulse-ox), is a way to determine the percent of
hemoglobin that carries oxygen. This measure is an indicator of
many physical parameters, including lung function. While the most
accurate method is to directly perform a gas analysis of arterial
blood, this approach is also incredibly invasive and rarely performed.
The standard of care is to measure the peripheral oxygen satura-
tion level. While systems based on monitoring changes in reflectance
and in transmission have been developed, measuring transmission
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is more commonly used due to its higher accuracy. Specifically, the
optical absorption of oxygenated hemoglobin is approximately an
order of magnitude higher than that of de-oxygenated hemoglobin
in the red blood cells (620 nm–700 nm), but in the near-IR, the val-
ues are nearly equal (800 nm–940 nm). Therefore, by comparing the
two signals, the percent of oxygenated hemoglobin can be calculated.
The initial optical pulse-ox systems date back to the early 1930s
and 1940s, but the systems were not in routine use in a medical
setting until the 1970s and 1980s. Moreover, these systems relied
on precision optical sources and were extremely sensitive to patient
motion, limiting their use to hospital settings. In the 1990s, sig-
nal analysis technology was developed to stabilize the signal against
patient motion. However, these systems still relied on precision light
sources and complex control systems. With the advent of low-cost
micro-LEDs with low power requirements that could be directly
integrated on-chip, finger-clip pulse-ox devices were designed and
developed. Inexpensive and suitable for at-home use, these sys-
tems have transformed cardiovascular care in both the hospital
and the home. Given the impact of COVID-19 on lung function,
these easy to use pulse-ox devices are now being used to mon-
itor the progression of COVID-19 patients from home,63–65 and
research is investigating their use as an “early warning system” for
COVID-19.66
III. EMERGING DIAGNOSTIC TECHNOLOGIES
A prominent area in integrated photonics focuses on the devel-
opment of biological and chemical sensors for diagnostics for a wide
range of diseases.34,37,47,67–71 Unlike the methods already discussed,
the emerging technologies directly leverage light–matter interac-
tions in the detection mechanism and have the possibility of being
integrated with microfluidics for high-throughput sample delivery
and analysis. High-throughput or multiplexing capability is of par-
ticular interest given diagnostic test shortages faced early on in the
COVID-19 pandemic.8 Two commonly used methods to detect and
identify specific substances in clinical samples are the detection of
refraction index and optical transmission changes and the detection
of optical scattering.
Beyond the well-known Surface Plasmon Resonance (SPR)
biosensor originally commercialized by Biacore, new sensing sys-
tems based on plasmonic nanotechnology72,73 and silicon-based
photonic rings and waveguides74,75 are continuously emerging to
provide the most appealing analytical features for rapid screen-
ing and diagnosis. As nanofabrication methods and optical com-
ponent integration have advanced, the portability of these plat-
forms has improved. Both sensors rely on the fundamentally
simple concept of evanescent field detection of refractive index
change.
Briefly, an evanescent wave generated at the interface of a
waveguide or a metallic nanostructure with the outer medium is
able to probe minute variations of the dielectric refractive index
and transduce them into variations of certain light properties, such
as resonance, intensity, or phase. By tethering specific bioreceptors
(e.g., antibodies or DNA probes) onto the sensor, the target ana-
lyte is captured from the sample. In this manner, the same surface
chemistry methods developed for the commercialized RDTs can be
leveraged to accelerate the design and translation of these optical
systems. Once the target analyte attaches to the sensor surface, the
refractive index of the local environment changes. Over a given con-
centration range, this change scales linearly with the analyte concen-
tration. Because of the role that available surface binding sites play
in generating the detection signal, one approach for controlling a
sensor’s operating range is to alter the density and composition of
binding sites. The idea of optimizing the surface chemistry to tailor
the working range is an emerging area of research.
The evanescent wave optical detection schemes with the high-
est sensitivity are those that track the frequency shift of resonance
or interferometry signals. Both signals are fundamentally monitor-
ing the local change in the refractive index caused by an analyte.
Resonance-shift methods monitor the change in a system’s reso-
nance frequency, such as that of a plasmonic nanoparticle or waveg-
uide, due to a local change in the refractive index caused by an
analyte. Interferometric methods monitor the phase change of an
optical probe signal due to local changes in the refractive index
caused by an analyte.35,37,49 This approach delivers quantitative data
in real time without the need of any fluorescent or colorimetric
labeling (i.e., label-free assay). The increased sensitivity allows for
a reduction in the requisite sample volume and reagents required,
making them ideal tools for decentralized and high-throughput
testing.74,76
In the last decade, label-free integrated photonic biosensors
have demonstrated their capabilities in analyzing clinically relevant
materials and reporting specific detection of proteins, nucleic acids,
or pathogens in human body fluids (serum, urine, saliva, etc.) with
outstanding assay sensitivity ranging from attomolar to femtomo-
lar (aM–fM) levels of RNA molecules to less than ten bacterial
cells, for example.76–79 They have also formed the foundation of
portable diagnostic systems for viral pathogen detection for Ebola
and malaria. This proven feasibility together with their unique ver-
satility positions photonic biosensor technologies as an attractive
solution for novel COVID-19 diagnostics.
Notably, optical technologies are being developed for two types
of detection of a SARS-CoV-2 viral infection: (1) direct and (2)
indirect. With direct detection, either the circulating viral RNA or
the virus itself is detected. The first approach is similar to RT-
qPCR in that the viral RNA is being detected. For these RNA sen-
sors, specific RNA target sequences are identified by hybridization
to a complementary nucleic acid sequence (i.e., DNA) immobi-
lized on the surface. If the biosensor is sensitive enough, it does
not need pre-amplification cycles based on PCR. This strategy rep-
resents a significant improvement over RT-qPCR and decreases
the time-to-result from over an hour for RT-qPCR to 10 min–
15 min (after RNA extraction). However, similar to qPCR, the
sensor is detecting the copies of viral RNA per ml of blood. The
second approach directly detects the circulating active viral parti-
cles, circumventing the basic limitation of PCR that has resulted
in false positives. Namely, PCR amplifies both circulating RNA
and RNA in active viral particles. Therefore, after a patient recov-
ers, there can still be circulating RNA that can be amplified and
detected. This circulating RNA can result in false positive sig-
nals. By detecting only intact viral particles, this limitation is
overcome.
Previous research on photonic biosensors has demonstrated
the genomic analysis of other respiratory virus infections: influenza,
respiratory syncytial virus (RSV), and other coronaviruses such
as the original SARS-CoV or the human coronavirus OC43/229E,
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responsible for common cold.41,80 However, in those cases, it was
necessary to perform prior or post-amplification procedures to
enhance the assay sensitivity. In general, genomic-based optical
biosensing assays could provide an alternative method to RT-qPCR,
meeting the sensitivity and specificity requirements for clinical diag-
nosis.
Soon after the COVID-19 outbreak, scientists started devel-
oping photonic biosensors for the detection of the SARS-CoV-
2 genomic material.81 In the previous work, the general strat-
egy of direct viral RNA detection using optical technologies has
been demonstrated using plasmonic and silicon photonic biosen-
sors. Notably, this approach allows for quantification of the viral
load, and overall sensitivities in the range of 102 copies/ml have
been demonstrated.82–84 This prior work formed a foundation for
developing detection technologies for SARS-CoV-2, and one of the
first works published during the pandemic reported a nanoplas-
monic biosensor for direct analysis of specific RNA fragments (RdRp
gene) of the novel coronavirus.81 The sensor, based on gold nanois-
lands, combines the localized SPR sensing with the plasmonic pho-
tothermal effect that enhances the selective hybridization of com-
plementary sequences while reducing non-specific binding of sim-
ilar targets [Fig. 6(a)]. Qiu et al. showed a detectability in the
picomolar (pM) range, estimating a limit of detection for entire
viral RNA strands around 104 copies/ml. The biosensor’s sensitiv-
ity could theoretically be appropriate for direct testing of clinical
specimens without PCR given that the viral load in throat/nasal
swabs of COVID-19 positive patients is usually between 105 and 106
copies/ml.
However, direct detection of the live virus particles is the ulti-
mate goal. By functionalizing the sensor surface with specific recep-
tors (e.g., antibodies) toward external proteins of the virus mem-
brane, it is possible to capture intact virus entities that circulate in
the body fluids, providing straightforward information of the live
viral load in the patient without the need for RNA extraction and/or
fragmentation procedures. To our knowledge, nothing has been
reported yet for the direct detection of SARS-CoV-2 viruses with
photonic biosensors, which is not surprising since the assay develop-
ment requires high-quality, specific antibodies that are more difficult
to produce than nucleic acid probes. However, several substantial
research efforts are underway.
CoNVat, one of the first large research projects in Europe
specifically dedicated to develop advanced nanophotonic biosen-
sors for diagnosis of coronavirus infection, is focused on waveg-
uide sensors. In particular, the goal of the research is to imple-
ment pioneering silicon photonics interferometric technology, the
Bimodal Waveguide (BiMW) biosensor,38 for SARS-CoV-2 detec-
tion [Fig. 6(b)]. This technology will offer an integrated approach
for accurate and quantitative diagnosis in less than 30 min.
One optical detection system has already proven effective
in detecting viruses, including Ebola and Marburg. It is based
on a simple interferometric reflectance imaging sensor (IRIS)
platform.13,85–91 The IRIS can not only detect but also count
individual viral pathogens in a complex medium without time-
consuming sample purification or preparation. The IRIS has a
unique detection mode from the previously discussed refractomet-
ric and fluorescence-based systems. Notably, when the virus binds
to the surface, its weight generates a detectable optical signal. This
is a label-free approach, and the detection signature is specific to
the physical size and properties of the virus, providing a secondary
signature for identification. In the previous work, the researchers
demonstrated a real-time detection limit of 100 PFU/ml for vesic-
ular stomatitis virus (VSV), and in response to the previous Ebola
epidemic, they developed a 20 min assay for the Ebola virions at
1.5 × 104 PFU/ml sensitivity corresponding to an average cycle
threshold (CT) of 23.1 on RT-PCR.90 Therefore, once optimized
for SARS-CoV-2 detection, this optical system is ideally suited to
accelerate diagnosis.
In addition to direct detection of the viral load, optical sensors
can also be used for indirect detection diagnostics or the detection
of the body’s antibody response.35,37,67,69 As previously discussed,
this type of assay is well-developed, and several relatively simple
constructs that can provide a simple yes/no determination have
been deployed. In contrast, photonic biosensors can quantify serum
antibodies. In previous epidemics and pandemics, optical biosen-
sors were developed for serological analysis of viral infections45,92–94
or have been used during vaccine development.95–97 In the cur-
rent COVID-19 pandemic, the development of biosensing proto-
cols for simple, rapid, and efficient serology testing could enable
biomedical and epidemiology research efforts, accelerating the dis-
covery of an optimum vaccine and improving our understanding of
SARS-CoV-2 in humans.
However, like any emerging research technologies, there are
numerous hurdles that must be overcome before these potentially
transformative devices can be translated. Notably, the integration
and full automation of operational sensing devices will require the
establishment of universal and reproducible protocols for bioassay
performance and the demonstration of reliability in large clinical
studies. In some cases, multiple optical components, including the
sensing elements as well as on-chip optical sources and detectors
or imagers, may be needed. By creating a cohesive package, the
FIG. 6. (a) Illustration of a dual-functional
nanoplasmonic biosensor for COVID-19
RNA analysis. Reproduced with permis-
sion from Qiu et al., ACS Nano 14, 5268
(2020). Copyright 2020 American Chem-
ical Society. (b) Illustration of a nanopho-
tonic bimodal waveguide interferometer
for direct sensing of intact SARS-CoV-2
viruses. CoNVaT project.
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noise level can be reduced, improving the overall system perfor-
mance. This level of system complexity will leverage recent advances
in heterogeneous fabrication protocols being developed. Addition-
ally, many of these systems can also be integrated with comple-
mentary electrical components, such as electrophoresis, as well as
microfluidics to move some aspects of sample preparation on-chip.
IV. DISINFECTION TECHNOLOGIES
While this immediate crisis is the catalyst, there is a global need
for the development of improved disinfection methods. Historically,
the majority of antibiotic-resistant bacterial infections originated in
medical settings. However, in 2019, there was a dramatic shift. Due
to the heroic efforts of the medical community to improve disin-
fection and sterilization, the number of infections originating in
medical settings decreased.98,99 However, the overall numbers con-
tinued their upward trajectory, due to community-based transmis-
sion. Moreover, many disinfection protocols assume ready access to
chemicals and generate significant environmental waste. Therefore,
to increase access to disinfection protocols in low-resource environ-
ments, reduce the environmental impact, and increase the usability,
alternative methods must be developed and evaluated.100–102
When designing a disinfectant method, the first step is to eval-
uate the key components of the biological contaminant. In the case
of coronavirus, the critical elements that ensure the stability, repli-
cation, and cell targeting ability are the envelope protein, RNA, and
spike glycoprotein, respectively.30,103–105 If any of these components
are destroyed, the virus will be inactivated. Therefore, most disinfec-
tion methods are designed to target one or more of these elements.
There are three general categories: thermal, chemical, and radia-
tion (Fig. 7). While the focus of this review is on radiation-based
methods, for comparison purposes, all three methods will be briefly
discussed.102
FIG. 7. Overview of disinfection strategies. (a) Basic structure of coronavirus (and
SARS-CoV-2), highlighting the key components needed for functioning. (b) Ther-
mal and (c) chemical disinfection methods degrade the spike protein and the
envelope protein. (d) Irradiation including UV-C degrades the RNA. Adapted with
permission from Stadler et al., Nat. Rev. Microbiol. 1, 209 (2003). Copyright 2003
Springer Nature. SARS-beginning to understand a new virus.
Thermal methods primarily target the spike glycoprotein with
secondary impact on the envelope protein, depending on the ther-
mal dose (heat and duration). Thermal methods were probably the
first disinfection method developed and can be as simple as boiling
water or an open flame. However, more rigorously controlled sys-
tems rely on ovens or other large chambers and can be either dry or
moist heat. Given that they uniformly treat a sample, they are par-
ticularly suitable for linens, though they can be used for a myriad of
supplies, such as surgical tools.
Chemical methods, including hydrogen peroxide and chlorine,
target the spike glycoprotein and the envelope protein.106,107 Both
vapor-based and handwipe chemical methods have been developed.
Due to their efficacy in removing both monolayers and larger quan-
tities of contaminants quickly, wipe-based chemical methods are the
preferred disinfection methods for surfaces or solid materials. How-
ever, one drawback of chemical methods is that they only destabilize
viruses that they directly interact with. To improve efficacy in mate-
rials with complex topologies, such as linens, a hybrid system is
frequently used, combining both thermal and chemical methods.
While technically being a chemical method, due to its distinct
mechanism, ozone (O3)-based disinfection is its own category. As
a powerful oxidant, ozone is able to destroy the glycoproteins and
the envelope proteins as well as all nucleotide bases comprising the
RNA. Because ozone is a gas, it is effective on porous media as well
as solid surfaces. Additionally, the process does not require high
temperatures, making it particularly attractive. However, ozone is
extremely reactive and readily returns to oxygen gas (O2). Therefore,
it is very challenging to use.
The most recent development in disinfection systems is
radiation-based systems. This category includes microwave, infrared
(IR), and UV-C systems. Microwave-based and IR-based systems
typically operate in an indirect manner. Namely, the microwaves
(or radio-frequency waves) excite water, which thermally heats and
destroys the spike glycoprotein. Thus, microwave radiation can be
considered a moist thermal disinfection. Similarly, since IR sources
are thermal sources, IR-systems can act as either dry or moist ther-
mal systems. In contrast, systems based on UV-C radiation operate
in a completely different manner.
RNA is comprised of four nucleotides: Adenine (A), Guanine
(G), Uracil (U), and Cytosine (C). They are grouped into two cat-
egories: purines (A, G) and pyrimidines (U, C). Typically, purines
bind to pyrimidines (A–U, G–C). However, when RNA is exposed
to 260 nm light, it initiates binding between pyrimidines.108,109 By
changing the fundamental structure of the RNA helix, RNA repli-
cation is inhibited, preventing viruses from reproducing. Therefore,
similar to chemical methods, the UV-C light must directly interact
with a virus particle to be effective. However, unlike chemical meth-
ods, UV-C does not expose the material to any kind of toxic chemi-
cal. Additionally, it can be performed at low temperatures. For these
reasons, the initial application of UV-C was in the environmen-
tal field, namely, for air purification and water disinfection.109–114
However, the airborne contagiousness of SARS-CoV-2 increased
the demand for new universal disinfection techniques to be
developed.
In the context of COVID-19, UV-C has proven particularly
effective in disinfecting PPE that protects healthcare workers against
airborne pathogens, primarily masks, face shields, and eyewear. This
ability has helped address the unprecedented spike in demand for
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those types of PPE that has threatened the safety of healthcare work-
ers. While governments worked to relax import restrictions to ease
the shock to PPE supply chains, during the worst part of the initial
COVID-19 crisis, healthcare workers in many countries were forced
to reuse their PPE at a dramatic scale. Although many countries are
past the initial COVID-19 peak, outbreaks are still expected to occur
throughout the world until a vaccine is widely available. This means
that spurious PPE shortages will be a continuing reality for the time
being, and it is worthwhile to investigate strategies that can enable
safe PPE reuse in times of crisis. UV-C provides one path to disinfect
PPE.
However, it is important to note that due to its universal dam-
age mechanism that destroys both DNA and RNA, UV-C can have
significant negative health effects on people as well as viruses, includ-
ing permanent blindness.108 Therefore, there are numerous safety
standards governing the use of UV-C light sources in the workplace.
For example, automatic shut-offs and the use of eye-protection
when using UV-C light sources are standard. However, many of
these safety standards are missing in consumer products that do
not undergo the same scrutiny. Given the rapid deployment of UV-
C based technologies into the consumer market, the lack of safety
standards is a growing concern.
One significant advantage of both thermal and radiation meth-
ods over chemical methods is that both thermal and radiation have
minimal consumables. This difference is notable for several rea-
sons. First, the amount of waste generated and the resulting envi-
ronmental impact are decreased as compared to those in chemi-
cal techniques. Additionally, the reliance on supply chains and on
manufacturing is reduced.
Unlike thermal treatments, UV disinfection protocols do not
require large ovens, and the fundamental mechanism is amenable
to high-throughput rates. They also may not necessarily require a
large financial investment or lead time prior to their use because
UV disinfectant tools come in a variety of forms, ranging from
small handheld wands to semi-autonomous robotic systems. A field
hospital established in 48 hours to deal with a COVID-19 out-
break may not be able to support the industrial-scale ovens with
high power requirements for thermal disinfection or the chemi-
cal vapor stations with gas purification needs for chemical disin-
fection, but it could purchase portable UV disinfection wands and
enclosures. Depending on the emitted UV power, the light sim-
ply needs to be held above the contaminated surface for a fixed
amount of time to ensure that the surface has been sterilized. This
can be as little as 10 s–30 s depending on the type of UV source
used.17,100,115–117
UV-C sources fall into two common categories: bulbs and
LEDs. Xenon or mercury bulbs are the most commonly used, hav-
ing originally formed the foundation of the industry. While they
are relatively inexpensive to make, they have high power require-
ments, which translate to high operating (or electrical) costs. Addi-
tionally, in comparison with that of alternative sources, their life-
time is short, and power cycling can further impact the lifetime.
An emerging alternative is UV-C LEDs. High power LEDs have
significantly reduced power demands and increased lifetime. They
also have smaller footprints, allowing more compact (or handheld)
systems to be designed. However, they are much more expensive,
increasing the “upfront” costs as compared to bulbs. Last, despite
being called “high power,” the LED output power is low to moderate
when compared to that of bulbs. To account for this difference, the
exposure time when using LEDs is increased in order to achieve the
same dose.117,118
Dosage is the product of intensity delivered to a surface and
time. Physical factors such as the distance between the source
and the surface and the source intensity profile play a role in
the calculation of how long a UV disinfectant tool needs to be
used in order to be effective against different pathogens. Fur-
ther complicating issues, different surface types (e.g., porous vs
non-porous) require different dosages. Given the mechanism of
UV-C, biological factors also contribute. Namely, because UV-
C is initiating dimerization of the pyrimidines, if the concentra-
tion of pyrimidines is higher, a lower dose can be used. Thus,
pathogens containing DNA, which is a double helix structure, intrin-
sically require a lower dose than RNA-based pathogens, includ-
ing viruses. For this reason, viral pathogens require the highest
dosages.
Last, there are two competing considerations: the desire to dis-
infect (damage) all viral and bacterial contaminants and the need to
not damage the surface, particularly for repeated exposures. There-
fore, determining the optimum dosage is a complex optimization
problem that must consider not only the specific pathogen but also
the UV-C source, the surface properties, and the specific application.
In the current climate, the two most common PPE disin-
fected using UV-C is N95 masks and face shields. These repre-
sent two very different surfaces, and their mechanism of acting
as PPE is very different. Face shields are either glass or chem-
ically resistant plastic, whereas N95 masks are fibrous (natural
or manmade). Therefore, while the face shield surface is con-
sidered non-porous and robust against relatively high doses of
UV-C (when compared to porous materials), N95 masks and sur-
gical masks are more delicate. Additionally, while chemical treat-
ments, including chemical immersion and wipes, can be used on
face shields, chemical compatibility can impact the porous struc-
ture of N95 masks, degrading the filtration ability, particularly with
repeated chemical disinfection. As a result, systems are typically
configured for either masks or shields, but not both. Similarly,
disinfection protocols are typically optimized for a single material
type.119
Thus far, three general approaches for PPE disinfection have
been studied: (1) reconfiguring standard biosafety cabinets,16 (2)
creating enclosed portable boxes with a single UV-C source or arrays
of UV-C sources,17 and (3) building large rooms with intense UV-C
sources located in the center. The first two approaches are capable
of disinfecting a few to a few dozen N95 masks or face shields at a
time, while the third technique can disinfect hundreds of N95 masks
at once. However, the infrastructure required for the third method
is significantly more expensive.
Given the important role that the material plays in the N95
mask filtration efficacy, the UV-C dosage thresholds for material
degradation have been extensively researched. In one study using
biosafety cabinets as the UV-C source, the balance between the
required dose to disinfect and the mask integrity was investigated.
It was shown the sterilizer cabinet had a slight impact on the fil-
tration efficiency of N95 masks (from the standard 95% to 93%)
after 20 cycles. For an N95 mask, ∼4.5 J/cm2 is the lowest dosage
at which no physical damage to N95 masks was observed, but this
varies substantially and values up to 120 J/cm2 may be acceptable in
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certain situations.15 This value establishes a “damage threshold” rule
of thumb for certain types of PPE.
Additionally, the environment around the mask during disin-
fection can play a role in damage. It is common to perform thermal
treatments in a moist or humid environment as the humidity accel-
erates the disinfection process. However, the humidity also damages
the masks, reducing the filtration to 80% after ten cycles.15 When
this value is compared to 95% filtration for a dry oven or the UV
sterilization cabinet, it is evident that the environment is a key factor
that should be considered and controlled.
While the material damage threshold provides an upper limit
to the total dose, the lower limit is set by the minimum dosage
required to disinfect a surface. In one study, it was established that a
17 mW/cm2 treatment for 30 min (30.6 J/cm2) was enough to safely
disinfect N95 masks against viral particles, allowing for ∼20 cycles
of this treatment before physical damage occurred (establishing a
damage threshold around ∼600 J/cm2).15 This work provides the
current basis for all UV-based disinfection techniques when using
N95 masks.
Given their reliability and environmental control, biosafety
cabinets and fixed enclosures are the standard approach for per-
forming UV-C disinfection in healthcare settings. However, UV-
C is also particularly amenable to creating handheld platforms
for consumer use. UV wands and small boxes for cellphones and
other personal items are battery-powered and are ideal for resource
constrained healthcare settings as well as personal use.
To disinfect larger surfaces around a room and objects that can-
not be moved, a mobile system is needed. Therefore, it is desirable
to create an autonomous or a semi-autonomous platform that can
disinfect these rooms or other large spaces routinely. In general, cur-
rent UV-C systems suitable for this task largely fall into one of the
two categories: passive robots that operate simply within their envi-
ronments and active robots that interact with components of their
environments. Each type of robot has its own advantages and dis-
advantages associated with its development, implementation, and
utilization.
The passive robots are much simpler systems, whose designs
typically involve a mobile base with fixed vertical UV-C sources
and are usually marketed as accomplishing “whole-room dis-
infection.” A few of these systems existed commercially prior
to the COVID-19 pandemic, motivated by the need to reduce
hospital acquired antibiotic-resistant bacterial infections.117,120–122
The fairly simplistic design of the most basic models allowed
the manufacturing of these robots to be rapidly increased,
and systems were beginning to be broadly distributed within
a few weeks of the pandemic being formally acknowledged
worldwide.
The design is primarily determined by the degree of auton-
omy, and the majority of systems rely on either pulsed xenon
lamps100,123–125 or mercury gas bulbs.125 One study has suggested
that the continuous dose of UV-C light provided by the mercury
bulbs is more effective at reducing pathogen levels than that pro-
vided by pulsed xenon lamps.125 These lights are mounted upright
on a mobile base, which ranges from a simple wheeled base that has
to be manually moved around to a robotic base that allows for more
autonomous use. Many of these systems have built-in safety mea-
sures, including motion-detecting sensors or lidar to detect people
and automatically shut off the bulbs to prevent harmful exposure.
Some also integrate sensory data and use software-based methods
to enhance and optimize the delivery of UV-C light throughout the
room, such as measuring reflected UV-C light to ensure that the low-
est dose delivered throughout the room meets the minimum dosage
required for disinfection.101
Studies of these passive robots have confirmed some of the
theoretical advantages of UV-C disinfection. Through their “no
touch” disinfection process, they remove the human error from
the process of disinfection and allow for more frequent clean-
ings since a person is not required to be present during oper-
ation of the robot. However, these robots still suffer from lim-
itations due to safety concerns; because they uniformly emit
UV-C light throughout a room, the room must be completely
empty of people to avoid potential harm. In addition, because UV-C
light diminishes in intensity proportional to the distance squared,
some hospitals have found the added inconvenience of position-
ing high-touch surfaces (such as mobile computer stands, hospi-
tals beds, and tables) around the UV-C robot125 or moving the
UV-C robot to several different positions within a room123 to be
necessary.
In addition, the inability of these passive robots to directly
interact with their environments due to limited sensing and a com-
plete lack of effectors significantly limits their disinfection capa-
bilities to only exposed surfaces. As a result, key surfaces within
hospital rooms that may be hidden from these passive robots
remain dirty. These could include occluded, high-frequency con-
tact surfaces, such as the surface of a counter hidden under a
box of gloves, the inside of an ADA door handle, or the back
of a door. One study has suggested that even some exposed sur-
faces are still not disinfected sufficiently, implying that the robots
may need to be “smarter” and interact more with the environ-
ment to provide more thorough disinfection.123 While these robots
still suffer from some limitations, the importance of the more sim-
plistic design should not be understated, as it had allowed these
robots to be successfully commercialized and deployed in hospi-
tals, rendering them immediately available during the COVID-19
pandemic.
More recently, there has been a push to develop robots with end
effectors to actively manipulate their environments to allow for more
comprehensive UV-C disinfection, particularly for high-trafficked
surfaces. These interactions can allow access to surfaces that were
occluded to the light provided by the passive robots. For instance,
a robot with arms that allow it to grab objects could move a box of
gloves to disinfect the surface of a counter underneath it or to pick
up a keyboard and expose it to UV-C light from different angles. A
robot with UV-C lights mounted to an arm, unlike the fixed UV-C
lights of the passive robots, could actively position its arm to dis-
infect surfaces that are difficult to access on immobilized objects or
between objects.
Because these robots require more complex control algorithms
to include the manipulation of their arms, development of these
active robots has taken longer than the design of the passive robots,
as evidenced by the availability of only passive robots in the com-
mercial market. Furthermore, these robots are most advantageous if
they are semi-autonomous or fully autonomous, freeing up a cru-
cial staff member who would otherwise be occupied controlling or
directing the robot. This requires the development of intricate plan-
ning algorithms, the integration of sensory input for the movement
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of these robots’ manipulators, and the design and construction of the
system.
Since the COVID-19 pandemic began, one Swiss startup has
been circumnavigating the long development period by adapting
a previous design. Rovenso has existing designs for mobile robots
for autonomous security and monitoring purposes, including a cus-
tom mobile base capable of navigating varying terrain and even
climbing stairs. Using a self-described “hack,” the Rovenso team
has attached a UV-C light source to their ROVéo robot, which was
originally designed to autonomously monitor the security of indus-
trial sites.126 Their design uses lidar to map the surrounding envi-
ronments and target highly used surfaces for UV-C disinfection.
However, Rovenso has designed their UV-C disinfection robot pri-
marily for use in non-medical spaces where less stringent cleaning
requirements are needed, such as offices and indoor workspaces.
Although UV-C cannot and should not replace thermal and
chemical disinfection in every scenario, UV-C can be used effec-
tively in many situations where thermal and chemical methods are
not possible or practical. Additionally, given the low consumable
requirements, UV-C is compatible with a wide range of operating
environments and can provide an alternative method, particularly
when supply chains are strained.
V. FUTURE OUTLOOK AND CONCLUSION
Optical technologies have directly contributed to both prevent-
ing the spread of and diagnosing COVID-19. This is truly indicative
of the ubiquitous nature of photonics technologies. While many
of the technologies discussed here are already in the community
and in healthcare settings, many are still in nascent stages of devel-
opment with their impact yet to be realized. Two areas that will
experience significant growth are the coupling between photonics
and robotics for automated disinfection and photonics, robotics,
and artificial intelligence (AI) for high-throughput diagnostics. Both
robotics and AI are experiencing intellectual revolutions with syner-
gistic advances, such as the development of autonomous robots. By
combining these intelligent automated systems with photonic-based
disinfection or diagnostic technologies, our approach to disinfection
and diagnostics could be revolutionized.
As mentioned previously, one of the initial uses of UV-C dis-
infection was in environmental applications, including air and water
purification, and this market remains the highest sector. Historically,
the majority of these units were used in conjunction with filtra-
tion systems to break down and remove contaminants related to
the spread of airborne mold or other asthma-related particulates.
However, given that COVID-19 spreads via airborne transmission,
the integration of UV-C into ventilation systems is one potential
approach under consideration for reducing transmission in indoor
settings. UV-C would be particularly attractive for this application
given its ability to disinfect without direct manual intervention.
However, several challenges for long-term, effective operation must
be considered, including the total dose required, the cost of oper-
ation, and the ability to replace the UV-C source. In this type of
system, high power UV LEDs would be the ideal source, given their
low cost of operation, their stable emission intensity over the life-
time, and their long operating lifetime. However, the initial cost of
high power UV LEDs is significantly more than that of mercury
bulbs. Thus, advances in photonics manufacturing will greatly drive
decision-making in this application. Last, it is important to note that
this type of system would not prevent direct person-to-person trans-
mission. In this context, the threat of infection from transmission
through ventilation systems has not been rigorously established.
In a related application, performing disinfection of surfaces that
we directly contact is manually intensive. As a result, it is challenging
to maintain a clean environment in high-traffic areas, such as public
transit, public bathrooms, and sports arenas. Therefore, these high
contact points carry a high risk of transmission. An autonomous
robot capable of operating independently would be able to reduce
transmission risk by disinfecting more frequently. This ability would
not only reduce infections during the present COVID-19 pandemic
but also improve overall healthcare in the future, as many seasonal
flu viruses are transmitted on surfaces. However, while this tech-
nology could have a clear positive societal impact, it is also impor-
tant to recognize and address the safety and ethical concerns.127,128
For example, an autonomous robotic system that could potentially
interact with people and pets would need to have integrated safety
measures to ensure that they were not exposed to the UV-C source.
In addition, discussions on the complex ethical landscape in AI and
robotics are currently ongoing.
Throughout the COVID-19 pandemic, it has become evident
that diagnosis is very complex, relying on advances in biotech-
nology as well as sensing methods. Additionally, there are many
types of samples that can be analyzed. For example, while nasal
swabs were the primary initial samples, more recent antibody
tests rely on blood. This diversity motivated the development of
a range of robotic sample handling systems that required smaller
sample volumes and used less reagents per test. Additionally, the
robotic systems accelerated the sample processing, enabling a sig-
nificant increase in throughput. However, many of these robotic
systems relied on proprietary plasticware and biological reagents.
As a result, shortages in either supply impacted diagnostic labs and
have motivated many facilities to develop their own supply chains.
This dependence on outside vendors, particularly for key reagents,
is always an important consideration when developing a new
diagnostic.
As discussed, in the antibody tests, both false positives and false
negatives can occur. Therefore, to improve accuracy, it is neces-
sary to evaluate not just a single test result, but the result in the
context of the patient’s other symptoms. Moreover, given the high
transmission risk, the time-to-result, or the speed with which a diag-
nostic test produces a result, is paramount. While optical sensors
produce results quickly, contextualization of the results relies on
additional information. By combining these results with a machine
learning-based AI optimized to contextualize the results, physicians
will be armed with the tools needed to make higher accuracy treat-
ment decisions on a faster timescale. Such a system not only would
advance the present COVID-19 treatment strategy but also could
change our approach to patient care.62,129 However, to be effec-
tive, machine learning systems require extensive learning libraries as
well as a better understanding of the disease pathophysiology.19,27,33
Because COVID-19 is so new, obtaining this key information is
extremely challenging.
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